Skip to main content
Premium Trial:

Request an Annual Quote

Stephan Herrera, Nassim Usman

Premium
Nektar Therapeutics, which is developing drugs based on proprietary pulmonary and pegylation technology platforms, this week appointed Stephan Herrera as its senior director of investor relations and corporate affairs.
 
Previously, Herrera held a similar role at Sirna Therapeutics, which was acquired by Merck earlier this year (see RNAi News, 1/4/2007). At Nektar, Herrera will work under President and CEO Howard Robin, who was formerly president and CEO of Sirna.
 

 
 
RXi Pharmaceuticals, the RNAi drugs spin out of CytRx, said this week that it has appointed Catalyst Biosciences CEO Nassim Usman to its scientific advisory board.
 
Prior to joining Catalyst, Usman held several positions at Sirna Therapeutics, including vice president of research and development, CSO, and COO. Usman left Sirna in 2005 (see RNAi News, 4/8/2005).

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.